M&A Deal Summary

Ligand Pharmaceuticals Acquires Apeiron Biologics

On July 8, 2024, Ligand Pharmaceuticals acquired life science company Apeiron Biologics for 100M USD

Acquisition Highlights

This is Ligand Pharmaceuticals’ 15th transaction in the Life Science sector.
This is Ligand Pharmaceuticals’ 3rd largest (disclosed) transaction.
This is Ligand Pharmaceuticals’ 1st transaction in Austria.

M&A Deal Summary
Date	2024-07-08
Target	Apeiron Biologics
Sector	Life Science
Buyer(s)	Ligand Pharmaceuticals
Deal Type	Add-on Acquisition
Deal Value	100M USD
Advisor(s)	Baker & McKenzie DORDA Rechtsanwälte (Legal)

Target

Apeiron Biologics

Vienna, Austria

Apeiron Biologics is a private biopharmaceutical company that co-developed QARZIBA (dinutuximab beta), a high-risk neuroblastoma drug, which it licensed to EUSA Pharma (UK) Limited (now a Recordati S.p.A. company) in 2016. The company also maintains a portfolio of more than 400 patents including the intellectual property and licenses for an early-stage immuno-oncology portfolio currently being developed by invIOs Holding AG which was spun-off from APEIRON in 2022. Apeiron Biologics was formed in 2000 and is based in

Search 200,500 Deals Now

SEARCH BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer